 MONT-SAINT-GUIBERT, Belgium, July 29, 2021 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that the Company will report first half 2021 financial and operating results on the evening of Wednesday, August 4, 2021. 